- Analytics
- Technical Analysis
Pfizer Technical Analysis - Pfizer Trading: 2023-05-18
Pfizer Inc. Technical Analysis Summary
Below 36.49
Sell Stop
Above 38.70
Stop Loss
| Indicator | Signal |
| RSI | Buy |
| MACD | Sell |
| Donchian Channel | Sell |
| MA(200) | Sell |
| Fractals | Sell |
| Parabolic SAR | Sell |
Pfizer Inc. Chart Analysis
Pfizer Inc. Technical Analysis
The technical analysis of the Pfizer stock price chart on daily timeframe shows #S-PFE,Daily is falling after hitting one-year high five months ago. The price has fallen below the 200-day moving average MA(200) which is falling itself. The RSI indicator is in oversold zone. We believe the bearish momentum will continue after the price breaches below the lower bound of the Donchian channel at 36.49. This level can be used as an entry point for placing a pending order to sell. The stop loss can be placed above 38.70. After placing the order, the stop loss is to be moved every day to the next fractal high indicator , following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (38.70) without reaching the order (36.49), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.
Fundamental Analysis of Stocks - Pfizer Inc.
Pfizer announced it is planning its largest debt offering to finance its proposed acquisition of Seagen Inc. Will the Pfizer stock price retreat reverse?
Pfizer Inc is planning to raise $31 billion which would be in eight tranches with the yield to maturity on 10-year bonds 125 basis points higher than the benchmark risk-free US 10-year Treasury. The company struck a $43 billion deal in March to acquire Seagen and its cancer therapies as it prepares for a steep fall in COVID-19 sales and generic competition for some top-selling drugs. Pfizer has been spending billions of dollars on research and acquisitions to mitigate an anticipated $17-billion hit to revenue by 2030 from patent expirations for top drugs and a decline in demand for COVID products. Pfizer’s shares edged down 0.7% after the bond offering news.
Explore our
Trading Conditions
- Spreads from 0.0 pip
- 30,000+ Trading Instruments
- Stop Out Level - Only 10%
Ready to Trade?
Open Account Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.
